Skip to main content

Table 1 Summary of EAE incidence, onset, and maximum disease severity in different murine models of MS upon antibody mediated blocking of VLA-4, MCAM, or VLA-4 and MCAM

From: Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus

Mouse Treatment Incidence Age (days)/day of onset Cumulative score
Integrin α4−/− Anti-MCAM 3/13 (23%) 19.3 ± 0.66 0.21 ± 0.12
Integrin α4−/− Isotype (MCAM) 6/16 (38%) 16.8 ± 0.65 0.38 ± 0.14
Devic Anti-VLA-4 1/11 (9%) 39 ± 0 0.01 ± 0.01
Devic Isotype (VLA-4) 7/11 (64%) 33.7 ± 1.5 0.58 ± 0.16
Devic Anti-MCAM 9/22 (41%) 34.3 ± 1.6 0.65 ± 0.19
Devic Isotype (MCAM) 12/21 (57%) 36.1 ± 1.4 0.79 ± 0.19
Devic Anti-VLA-4/MCAM 2/11 (18%) 35.5 ± 3.5 0.09 ± 0.07
Devic Isotype (VLA-4/MCAM) 9/11 (82%) 30 ± 1.7 1.54 ± 0.09
  1. The age/day of onset and the cumulative score are means ± SEM